Significance of mesothelin expression in preoperative endoscopic biopsy specimens for colorectal cancer prognosis.
Pathology
colorectal cancer
endoscopic biopsy specimen
immunohistochemistry
mesothelin
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
27 Oct 2020
27 Oct 2020
Historique:
received:
09
07
2020
accepted:
29
09
2020
entrez:
16
11
2020
pubmed:
17
11
2020
medline:
17
11
2020
Statut:
epublish
Résumé
Mesothelin (MSLN) is a cell surface glycoprotein that is normally expressed in the mesothelial cells but highly expressed in several malignant tumors, where the high expression is generally associated with poor prognosis. In this work, 512 patients with stage III colorectal cancer (CRC) were examined to ascertain the prognostic value of MSLN expression in preoperative endoscopic biopsy specimens. MSLN expression was evaluated by immunohistochemical staining. The tumor cells were MSLN-positive in 61 of the 512 patients (11.9%). MSLN expression was associated with a shorter disease-specific survival (DSS) period (5-year DSS = 68.7%,
Identifiants
pubmed: 33196692
doi: 10.18632/oncotarget.27774
pii: 27774
pmc: PMC7597413
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3807-3817Informations de copyright
Copyright: © 2020 Shiraishi et al.
Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST The authors disclose that they have no significant relationships with or financial interest in any commercial companies related to this article.
Références
Virchows Arch. 2020 Sep;477(3):409-420
pubmed: 32107600
Cancer. 2002 Dec 1;95(11):2422-30
pubmed: 12436451
Am J Surg Pathol. 1999 Oct;23(10):1248-55
pubmed: 10524526
BMC Dev Biol. 2003 Apr 7;3:2
pubmed: 12697065
Mol Cancer. 2017 Mar 14;16(1):63
pubmed: 28288645
Clin Cancer Res. 2001 Dec;7(12):3862-8
pubmed: 11751476
Int J Cancer. 2001 Sep 20;95(5):290-4
pubmed: 11494227
Int J Cancer. 1992 Feb 1;50(3):373-81
pubmed: 1735605
Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):136-40
pubmed: 8552591
Lab Invest. 2005 Feb;85(2):257-66
pubmed: 15516972
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Dis Colon Rectum. 2019 Nov;62(11):1316-1325
pubmed: 31567925
Int J Clin Oncol. 2020 Jan;25(1):1-42
pubmed: 31203527
Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3937-42
pubmed: 15217923
Int J Mol Med. 2002 Nov;10(5):547-50
pubmed: 12373289
Appl Immunohistochem Mol Morphol. 2005 Sep;13(3):243-7
pubmed: 16082249
Am J Clin Pathol. 2011 Jul;136(1):138-44
pubmed: 21685041
Jpn J Clin Oncol. 2015 Jun;45(6):533-40
pubmed: 25770060
Virchows Arch. 2019 Mar;474(3):297-307
pubmed: 30603773
J Anus Rectum Colon. 2019 Oct 30;3(4):175-195
pubmed: 31768468
Br J Cancer. 2009 Apr 7;100(7):1144-53
pubmed: 19293794
Cancer Metastasis Rev. 1985;4(1):27-39
pubmed: 3888381
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571